AMRX: Amneal Pharmaceuticals, Inc. Stock

by  •  • Comments Off on AMRX: Amneal Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 1,683.16
Enterprise Value ($M) 4,273.49
Book Value ($M) 61.30
Book Value / Share 0.20
Price / Book 27.46
NCAV ($M) -2,033.40
NCAV / Share -6.59
Price / NCAV -0.83

Profitability (mra)
Return on Invested Capital (ROIC) -0.03
Return on Assets (ROA) -0.02
Return on Equity (ROE) -0.52

Liquidity (mrq)
Quick Ratio 0.94
Current Ratio 1.63

Balance Sheet (mrq) ($M)
Current Assets 1,377.86
Assets 3,472.57
Liabilities 3,411.26
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 2,393.61
Operating Income 270.65
Net Income -83.99
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 345.58
Cash from Investing -69.19
Cash from Financing -212.57

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-13 13G/A Vanguard Group Inc 4.45 4.55
01-05 13G Mahesh Akram 9.90
01-03 13D/A Patel Gautam 0.07 -94.02
12-12 13G/A Fosun International Ltd 6.00 0.00
11-08 13D/A Patel Chirag K. 7.10 0.00
11-08 13D/A Patel Tushar Bhikhubhai 17.50 0.00
11-08 13D/A Patel Chintu 8.30 0.00
11-08 13D/A Patel Dipan 8.80 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-14 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K
2023-11-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S
2023-05-09 10-Q filed May 9, 2023

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-17 228,070 1,220,455 18.69
2024-04-16 135,229 1,203,914 11.23
2024-04-15 182,956 1,117,966 16.37
2024-04-12 610,075 2,184,811 27.92

(click for more detail)

Similar Companies
AMGN – Amgen Inc. AMLX – Amylyx Pharmaceuticals, Inc.
AMPH – Amphastar Pharmaceuticals, Inc. ANAB – AnaptysBio, Inc.
ANNX – Annexon, Inc.


Financial data and stock pages provided by
Fintel.io